ClinicalTrials.gov
public full text
Public Domain
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma#832662
- A Sequential Dose-Escalation Study in Subjects With Mild Asthma#827672
- Nebulized Versus Intravenous Magnesium Sulfate in Treatment of Asthma Exacerbation#864600
- A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma#810733
- Assessment of the Safety and Efficacy of Dupilumab in Children With Asthma (Liberty Asthma Excursion)#907133
Record · ID 910224
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive